We are live on ! Find out more
VPC

Vestal Point Capital Portfolio holdings

AUM $3.58B
1-Year Est. Return 189.12%
This Fund
S&P 500
This Quarter Est. Return
+63.68%
1 Year Est. Return
+189.12%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$2.94B
AUM Growth
+$727M
Cap. Flow
+$234M
Cap. Flow %
7.95%
Top 10 Hldgs %
50.17%
Holding
105
New
24
Increased
24
Reduced
21
Closed
29

Top Buys

Rank Stock Value
1
ACLX
Arcellx
ACLX
+$134M
2
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$118M
3
TERN
Terns Pharmaceuticals
TERN
+$104M
4
ABVX
Abivax
ABVX
+$98.2M
5
MRK icon
Merck
MRK
+$72.7M

Top Sells

Rank Stock Value
1
NUVL
Nuvalent
NUVL
+$104M
2
ASND icon
Ascendis Pharma A/S
ASND
+$87.8M
3
FOLD
Amicus Therapeutics
FOLD
+$76.8M
4
IONS icon
Ionis Pharmaceuticals
IONS
+$70.3M
5
BDX icon
Becton Dickinson
BDX
+$60.8M

Sector Composition

Rank Sector Weight
1 Healthcare 92.69%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ABVX
1
Abivax
ABVX
$11.2B
$256M 8.71%
1,900,000
+900,000
+90% +$98.2M
QQQ icon
2
PUT
Invesco QQQ Trust
QQQ
$449B
$215M 7.31%
+350,000
New +$215M
ACLX
3
DELISTED
Arcellx
ACLX
$191M 6.48%
2,925,000
+1,675,000
+134% +$134M
TERN
4
DELISTED
Terns Pharmaceuticals
TERN
$182M 6.18%
+4,500,000
New +$104M
BMRN icon
5
BioMarin Pharmaceuticals
BMRN
$11.6B
$178M 6.06%
3,000,000
+2,170,000
+261% +$118M
GMED icon
6
Globus Medical
GMED
$10.6B
$111M 3.78%
1,275,000
+25,000
+2% +$1.9M
NRIX icon
7
Nurix Therapeutics
NRIX
$2.43B
$89M 3.02%
4,690,000
+1,215,000
+35% +$17.5M
ALC icon
8
Alcon
ALC
$32.8B
$87.1M 2.96%
1,105,000
+5,000
+0.5% +$385K
DXCM icon
9
DexCom
DXCM
$28.3B
$84.6M 2.88%
1,275,000
+625,000
+96% +$40.4M
MRK icon
10
Merck
MRK
$323B
$81.6M 2.77%
+775,000
New +$72.7M
TSHA icon
11
Taysha Gene Therapies
TSHA
$1.59B
$75.6M 2.57%
13,750,000
+8,250,000
+150% +$40.1M
ABT icon
12
Abbott
ABT
$182B
$75.2M 2.56%
600,000
+350,000
+140% +$44.6M
IMTX icon
13
Immatics
IMTX
$1.18B
$64.3M 2.19%
6,125,000
-225,000
-4% -$2.27M
TYRA icon
14
Tyra Biosciences
TYRA
$1.85B
$63.8M 2.17%
2,425,000
– –
BCAX
15
Bicara Therapeutics
BCAX
$1.83B
$60.2M 2.05%
3,575,000
-1,525,000
-30% -$26M
ARWR icon
16
Arrowhead Research
ARWR
$12B
$59.8M 2.03%
+900,000
New +$44.1M
ELVN icon
17
Enliven Therapeutics
ELVN
$3.77B
$59M 2.01%
3,830,000
+2,670,000
+230% +$53.2M
IRON icon
18
Disc Medicine
IRON
$2.85B
$58.4M 1.98%
735,000
+235,000
+47% +$19.9M
JAZZ icon
19
Jazz Pharmaceuticals
JAZZ
$16B
$49.3M 1.68%
290,000
-210,000
-42% -$32.2M
DAWN
20
DELISTED
Day One Biopharmaceuticals
DAWN
$48.5M 1.65%
5,200,000
+2,525,000
+94% +$21.1M
LXEO icon
21
Lexeo Therapeutics
LXEO
$351M
$44.4M 1.51%
4,475,000
+1,225,000
+38% +$11.2M
ANRO icon
22
Alto Neuroscience
ANRO
$1.08B
$44.2M 1.5%
2,485,000
+1,535,000
+162% +$19.3M
APGE icon
23
Apogee Therapeutics
APGE
$10.2B
$41.5M 1.41%
550,000
+125,000
+29% +$7.87M
OLMA icon
24
Olema Pharmaceuticals
OLMA
$1.05B
$41.3M 1.4%
+1,650,000
New +$29.4M
AXSM icon
25
Axsome Therapeutics
AXSM
$12.3B
$38.4M 1.3%
210,000
+60,000
+40% +$8.38M
1
2 3 4 5

Similar funds

WWA
WCG Wealth Advisors Las Vegas, Nevada $3.57B AUM 18.63% 1-Year Est. Return
BPS
BNDES Participacoes SA Rio De Janeiro, Brazil $3.58B AUM
RSWM
Robertson Stephens Wealth Management San Francisco, California $3.57B AUM 28.36% 1-Year Est. Return
SPC
Sigma Planning Corp Ann Arbor, Michigan $3.6B AUM 24.57% 1-Year Est. Return
U
Uber San Francisco, California $3.6B AUM 19.81% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
AAP
Arax Advisory Partners Denver, Colorado $3.54B AUM 19.14% 1-Year Est. Return
WB
WesBanco Bank Wheeling, West Virginia $3.61B AUM 24.09% 1-Year Est. Return

Vestal Point Capital's Q4 2025 Portfolio in Review

As of Q4 2025, Vestal Point Capital held 105 positions worth $2.94B, up 33% from $2.21B the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Vestal Point Capital deployed $234M of net new capital in Q4 2025, opening 24 new positions and adding to 24 existing holdings. Its largest new stake was Terns Pharmaceuticals: 4,500,000 shares worth $182M.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, down from 100% a quarter earlier.

On the sell side, the largest reduction was Nuvalent, an estimated $104M trimmed.

  • Vestal Point Capital's largest Q4 2025 buy was Terns Pharmaceuticals: 4,500,000 shares worth $182M.
  • Vestal Point Capital added most to Arcellx in Q4 2025, an estimated $134M increase.
  • Vestal Point Capital's biggest Q4 2025 reduction was Nuvalent, cutting an estimated $104M.
  • Vestal Point Capital fully exited Amicus Therapeutics in Q4 2025, selling an estimated $76.8M.
  • Vestal Point Capital's ten largest holdings make up 50% of its $2.94B portfolio in Q4 2025.
  • Vestal Point Capital opened 24 new positions and closed 29 in Q4 2025.
  • Vestal Point Capital's portfolio value rose 33% quarter-over-quarter to $2.94B.

Based on Vestal Point Capital's 13F filing for Q4 2025, filed 17 Feb 2026.